

Fellow Publications/Presentations January through December 2014

Publications

1. Entezari V1, **Agwa E**, Ruiz SJ, Lietman SA, Silver BJ, Jegalian AG. Hemophagocytic lymphohistiocytosis secondary to localized large B-cell lymphoma in a patient with history of knee arthroplasty. *Leuk Lymphoma*. 2014 Oct 7;1-3. [Epub ahead of print] PMID:25178490[PubMed]
2. **Agwa ES**, Ma PC. Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib. *Cancer Manag Res*. 2014 Oct 4;6:397-404. doi: 10.2147/CMAR.S37345. eCollection 2014. Review. PMID: 25328417
3. **Ai J**, Advani A. Current status of antibody therapy in ALL. *Br J Haematol*. 2014 Nov 10. doi: 10.1111/bjh.13205. [Epub ahead of print] PMID: 25382151 [PubMed - as supplied by publisher]
4. **Ai J**, Tiu RV. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations. *Ther Adv Hematol*. 2014 Aug;5(4):107-20. doi: 10.1177/2040620714537865. Review. PMID: 25360237 [PubMed]
5. **Ai J**, Stevenson JP. Current issues in malignant pleural mesothelioma evaluation and management. *Oncologist*. 2014 Sep;19(9):975-84. doi: 10.1634/theoncologist.2014-0122. Epub 2014 Jul 24. PMID: 25061089
6. **Keng MK** and Sekeres MA. Leukemia. In, Stoller JK, Nielsen C, Buccola J, Brateanu A, editors. *Cleveland Clinic Intensive Review of Internal Medicine*, Sixth Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2014.
7. **Keng MK** and Advani AS. The Myeloproliferative Neoplasms. *Current Clinical Medicine*. Ed. Carey W. Elsevier, Inc. 2014. Available at: <http://www.clevelandclinicmeded.com/diseasemanagement>. [Accepted].
8. **Keng MK** and Sekeres MA. Acute Myeloid Leukemia. *Current Clinical Medicine*. Ed. Carey W. Elsevier, Inc. 2014. Available at: <http://www.clevelandclinicmeded.com/diseasemanagement>. [Accepted].
9. **Keng MK** and Sekeres MA. The Myelodysplastic Syndromes. *Current Clinical Medicine*. Ed. Carey W. Elsevier, Inc. 2014. Available at: <http://www.clevelandclinicmeded.com/diseasemanagement>. [Accepted].
10. **Mittal K**, Ebos J, Rini B. Angiogenesis in the Tumor Microenvironment. *Seminars in Oncology* 2014; 41(2):235-51. PMID 24787295
11. **Mittal K**, McNamara M, Curtis B, McCrae K. Persistence of Antiplatelet Antibodies in Oxaliplatin Induced Immune Thrombocytopenia. *Journal of the Royal Society of Medicine* 2014 (*In press accepted manuscript*)
12. **Mittal K**, Borden E, Rini BI. Phase I trial of sunitinib and bevacizumab in patients with advanced solid malignancies PMID 24842548 (*In press accepted manuscript Cancer Biology and Therapy*)
13. Najjar Y, **Mittal K**, Elson P, Wood L, Garcia J, Dreicer R, Rini B. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. *European Journal of Cancer* 2014; 50(6):1084-9
14. Najjar YG, **Mittal K**, Faza NN, Dushkin H, Peereboom DM. Isolated secondary CNS relapse in a case of stage I diffuse large B-cell lymphoma. *BMJ Case Rep*. 2014 May 5;2014. pii: bcr2013201442. doi: 10.1136/bcr-2013-201442. PMID: 24798352 [PubMed - indexed for MEDLINE]
15. **Mittal K**, Sharma K, Dangayach N, Raval D, Leung K, George S, Abraham G. Use of a standardized code status discussion by residents amongst hospitalized patients. *Journal of Community Hospital Internal Medicine Perspectives* 2014; 4: 23745. PMID 24765258

16. **Mi K**, Kalady MF, Quintini C, Khorana AA. Integrating Systemic and Surgical Approaches to Treating Metastatic Colorectal Cancer. *Surg Oncol Clin N Am*. 2015 Jan;24(1):199-214. doi: 10.1016/j.soc.2014.09.006. PMID: 25444476 Epub 2014 Oct 7. Review.
17. **Nazha A**, Kantarjian HM, Bhatt VR. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics., Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. *Clin Lymphoma Myeloma Leuk*. 2014 Apr;14(2):163-71. doi: 10.1016/j.clml.2013.07.009. Epub 2014 Jan 22.
18. Strati P, Kantarjian H, Ravandi F, **Nazha A**, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *Am J Hematol*. 2014 Dec 22. doi: 10.1002/ajh.23924. PMID: 25530214 [Epub ahead of print]
19. **Nazha A**, Jorgensen JL, Verstovsek S. Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis. *Leuk Lymphoma*. 2014 Sep;55(9):2215-6. doi: 10.3109/10428194.2013.876628. PMID: 24359246 Epub 2014 Jan 24.
20. Zhao X, Bodo J, **Sun D**, Durkin L, Lin J, Smith MR, Hsi ED. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. *Br J Haematol*. 2014 Oct 4. doi: 10.1111/bjh.13149. [Epub ahead of print] PMID: 25284608

Poster Presentations/Abstracts

1. **Agwa E**, Chao S, Lingling Du, Alva Venur V, Elson P, Barnett G, Angelov L, Suh J, Ahluwalia M. Validation study of graded prognostic assessment (GPA) of non-small cell lung cancer (NSCLC) patients with brain metastasis (BM). ASCO Annual Meeting 2014 (Poster)
2. **Ai J**, Visconte V, Tabarroki A, Hasrouni E, Hamilton B, Mukherejee S, Kalaycio M, Sobecks R, Advani A, Sekeres M, Shetty S, Tiu R. Poor Survival Outcomes In Myelodysplastic Syndrome Patients With Non-t(6;9) And Non-inv(3) Balanced Chromosomal Rearrangements Are Influenced By SRSF2 Mutations. ASH Annual Meeting, San Francisco, CA. December, 2014 (Poster)
3. **Chi M**, Graded prognostic assessment for triple negative breast cancer brain metastases. San Antonio Breast Cancer Symposium, December, 2014. (Poster)
4. **Fu S**, Kelly K, Espitia C, Han Y, Carraway H, Advani A, Maciejewski J, Sekeres M, Steffan N, Carew J. The Novel Plk Inhibitor Volasertib Overcomes Cytarabine Resistance in Acute Myeloid Leukemia. ASH Annual Meeting, San Francisco, CA. December 2014. (Poster)
5. **Goodman LM**, et al. The Morbidity and Mortality Conference (MMC) in Oncology: A patient safety and root cause analysis (RCA)-driven approach at the Cleveland Clinic Taussig Cancer Institute (TCI). *J Clin Oncol* 32, 2014 (suppl 30; abstr 191). ASCO (Poster)
6. **Goodman LM**, et al. Improving prophylactic growth factor (pGCSF) use in non-small cell lung cancer (NSCLC) patients (pts) receiving chemotherapy (CT) at the Cleveland Clinic Taussig Cancer Institute (TCI). *J Clin Oncol* 32, 2014 (suppl 30; abstr 83). ASCO (Poster)
7. **Goodman L**, Montero A, Rybicki L, Mrazek K, Calhoun B, Tubbs R, Moore H. Clinical Outcomes of Breast Cancer Patients with Intermediate Oncotype DX Recurrence Scores (RS): A Review of the Cleveland Clinic Experience. San Antonio Breast Cancer Symposium, December, 2014. (Poster)

8. **Keng MK**, Thallner E, Elson P, Zayac C, Sekeres J, Wenzell CM, Gallagher EM, Weber CM, Earl MA, Mukherjee S, Seastone DJ, Pohlman B, Cober E, Rodgers B, Foster VB, Yuhas J, Kalaycio ME, Bolwell BJ, Sekeres MA. Defining quality and value in a prospective study of an emergency department (ED) febrile neutropenia pathway (FNP). [Poster]. JCO 2014.
9. **Mittal K**, Derosa L, Albiges L, et al. Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients. ASCO Poster Highlights Session, 2014
10. **Mittal K**, Williams A, Rawal S, et al. Circulating tumor cell kinetics in mRCC patients treated with sunitinib. ASCO GU Symposium, 2014 *J Clin Oncol* 32, 2014 (suppl 4; abstr 481)
11. **Nazha A**, Seastone DJ, Radivoyevitch T, et al. A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS). 56th ASH annual meeting, San Francisco, December, 2014. (Oral)
12. **Nazha A**, Seastone DJ, Radivoyevitch T, et al. A Novel Prognostic Model for Risk Stratification in Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML). Society of Hematologic Oncology 2014 Annual Meeting, Houston, September, 2014. (Oral)
13. **Nazha A**, Seastone DJ, Priyanka A Pophali, et al. Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype. 56th ASH annual meeting, San Francisco, December, 2014. (Poster)
14. **Nazha A**, Sekeres MA, Garcia-Manero G, et al. Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA). 56th ASH annual meeting, San Francisco, December, 2014. (Poster)
15. **Nazha A**, Radivoyevitch T, Seastone DJ, et al. Differences in Genomic Patterns and Clinical Outcomes Between African-American and White Patients with Myelodysplastic Syndromes (MDS). 56th ASH annual meeting, San Francisco, December, 2014. (Poster)
16. **Nazha A**, Komrokji R, Garcia-Manero G, et al. The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. 56th ASH annual meeting, San Francisco, December, 2014. (Poster)
17. **Nazha A**, Seastone DJ, Radivoyevitch T, et al. Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS). 56th ASH annual meeting, San Francisco, December, 2014. (Poster)
18. **Seastone DJ**, Aziz N, Priyanka P, Ornstein M, Carraway H, Advani A, Gerds A, Kalayacio M, Maciejewski J, Sekeres M. Assessing the Value of Echocardiograms for Patients with Acute Myeloid Leukemia (AML) Receiving Anthracyclines. ASH Annual Meeting. December, 2014 (Poster)
19. **Sun D**, Hill B, Rybicki L, Roupail B, Dean R, Jagadeesh D, Hamilton B, Gerds A, Sobecks R, Andresen S, Duong H, Navneet M, Pohlman B, Kalaycio M, Bolwell B, Smith M. Efficacy of Standard Dose R-CHOP Alternating with R-HiDAC Followed by ASCT as Initial Therapy of Mantle Cell Lymphoma: Cleveland Clinic Experience. ASH Annual Meeting. December, 2014 (Poster)
20. Yao J, **Sun D**, Galehouse D, Shorten S, et. al. HER2 Δ 16 expression in HER2 positive breast cancer. 2014 Breast Cancer Symposium (Abstract #31, poster).
21. **Swapna T**, Hideki M, Bartlomiej P, Aaron D, Bhumika P, et. al. The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies. ASH Annual Meeting. December 2014. (Poster)